SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027
Scienture Holdings issued a shareholder letter reporting preliminary unaudited Q3 2026 revenue of approximately $1.22 million, a 256% sequential increase over Q2's $343,639. Growth was driven by a 74% sequential increase in Arbli wholesale unit sales plus initial wholesale shipments of REZENOPY, launched in August 2026 as the company's second FDA-approved product. Q2 2026 gross margins were approximately 97.7%, with net loss narrowed 58% year-over-year to $2.8 million; management targets profitability in 2027 on operating leverage.
Key figures
- Revenue
- 1220000
- Guidance
- Continued sequential revenue growth and targeted profitability in 2027
- Revenue Yoy
- not stated
- Q2 2026 revenue
- 343639
- Q2 2026 net loss
- 2800000
- Arbli market size
- $218 million annual U.S. losartan market
- Gpo facility access
- 5,000+ healthcare facilities
- Gross margin q2 2026
- 97.7%
- Naloxone market size
- $137 million annual U.S. naloxone nasal spray market
- Net loss narrowing yoy
- 58%
- Q2 2026 operating loss
- 2700000
- Covered lives potential
- 100 million+
- Sequential revenue growth
- 256%
- Q2 2026 operating expenses
- 3000000
- Arbli wholesale unit growth
- 74%
- Operating loss improvement yoy
- 48%
- Operating expense reduction yoy
- 41%
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.